Non-fatal heart failure risk occurring in type 2 diabetic patients receiving rosiglitazone therapy:a meta-analysis
Wu Shanshan,Zhang Yuan,Sun Feng,Zhan Siyan
DOI: https://doi.org/10.3969/j.issn.1008-5734.2011.03.005
2011-01-01
Abstract:Objective:To systematically evaluate the non-fatal heart failure risk occurring in type 2 diabetic patients receiving rosiglitazone therapy.Methods:Medline,ClinicalTrials.gov website and GlaxoSmithKline(GSK) website were searched using "rosiglitazone","randomized clinical trial" and "human'as the keywords from the inception to 31 August,2010.The randomized controlled trials(RCT) to compare non-fatal heart failure risk of rosiglitazone and other hypoglycemic drugs in patients with type 2 diabetes mellitus were collected and meta-analysis were conducted.According to the treatment course,diabetes duration,therapeutic model and type of control,all RCT were divided into different subgroups to undergo meta-analysis;and sensitivity analysis and cumulative meta-analysis were conducted further.Results:A total of 678 related articles were searched and 170 trials were obtained according to the inclusion and exclusion criteria.Of the 170 trials,99 were openly published on Medline or the website of ClinicalTrials.gov and 71 were published on the website of GSK.The results of meta-analysis showed that the odds ratio(OR) for nonfatal heart failure in the rosiglitazone group was 1.24(95%CI:0.99-1.55,P = 0.065),compared with the control group.The results of meta-analysis in subgroups showed that the OR for non-fatal heart failure in the rosiglitazone group were 1.42(95%CI: 1.06-1.90,P=0.019) and 1.01(95%CI:0.71-1.44,P = 0.958) in the 99 openly published studies and the 71 studies published on the website of GSK,respectively;the OR for non-fatal heart failure in the rosiglitazone group was 1.62(95%CI:1.17-2.23,P = 0.004) in the 30 studies with the treatment course of≥52 weeks.In the 21 openly published studies with the treatment course of≥52 weeks and the 33 studies with the duration of diabetes of≥5 and<10 years,the OR for non-fatal heart failure in the rosiglitazone groups were 1.79(95%CI:1.22-2.64,P = 0.003) and 1.55(95%CI:1.06-2.26,P= 0.025),respectively.The results of cumulative meta-analysis showed that the OR value was influenced by the results of the large scale RCT(RECORD) 2009,and there was a positive turning point in 2009.The results of a meta-analysis of the 43 trials with a JADA score of≥3 showed that the OR for non-fatal heart failure was 1.62(95%CI:1.17-2.23,P=0.004);of them,the OR values for the 16 trials with the treatment course of≥52 weeks,the 13 trials with the duration of diabetes of≥5 and<10 years,and the 19 trials with combined drug therapy were 1.79(95%CI:1.24-2.57,P=0.002),1.76(95%CI:1.15-2.71,P =0.010),and 1.68(95%CI:1.11-2.53,P = 0.014), respectively.Conclusion:Rosiglitazone may increase the non-fatal heart failure risk in the patients with type 2 diabetes mellitus, particularly in those with long duration of diabetes,receiving long-term medication use and combined drug therapy.